



IFW

Patent Application
Attorney Docket No. PC25489A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 21st day of June 2004

By _____

Irene Grantham

(Signature of person mailing)

Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gillian Munro Burgess, et al.

APPLICATION NO.: 10/799,191 : Examiner: To Be Assigned

FILING DATE: March 12, 2004 : Group Art Unit: To Be Assigned

TITLE: TREATMENT OF TYPE 1 DIABETES WITH PDE5 INHIBITORS

Mail Stop Amendments

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application
Attorney Docket No. PC25489A

A prompt and favorable response is earnestly solicited.

Date: June 21, 2004
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC25489A			SERIAL NO. 10/799,191		
								APPLICANT Gillian Munro Burgess, et al.					
								FILING DATE March 12, 2004			GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE
	US	2002-	00	1	9	5	6	3	2/14/02	Webber, et al.	562	477	
	US	5	0	0	6	5	3	0	4/9/91	Angerbauer, et al.	514	277	
	US	5	1	7	7	0	8	0	1/5/93	Angerbauer, et al.	514	277	
	US	5	5	7	6	3	2	2	11/19/96	Takase, et al.	514	260	
	US	5	6	9	8	5	6	0	12/16/97	Onoda, et al.	514	267	
	US	6	1	0	6	8	6	4	8/22/00	Dolan, et al.	424	488	
	US	6	4	7	9	4	9	3	11/12/02	Whitehead, et al.	514	241	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	YES	NO											
WO	9	1	1	1	1	7	2	8/8/91	PCT	A61K	9/00		
WO	9	3	0	6	1	0	4	4/1/93	PCT	C07D	487/04		
WO	9	3	0	7	1	4	9	4/15/93	PCT	C07D	487/04		
WO	9	3	1	2	0	9	5	6/24/93	PCT	C07D	239/91		
WO	9	4	0	0	4	5	3	1/6/94	PCT	C07D	473/30		
WO	9	4	0	2	5	1	8	2/3/94	PCT	C08B	37/16		
WO	9	4	0	5	6	6	1	3/17/94	PCT	C07D	471/04		
WO	9	5	1	9	9	7	8	7/27/95	PCT	C07D	471/14		
WO	9	6	2	1	6	5	6	7/18/96	PCT	C07D	295/08		
WO	9	8	4	9	1	6	6	11/5/98	PCT	C07D	487/04		
WO	9	8	5	5	1	4	8	12/10/98	PCT	A61K	47/48		
WO	9	9	1	1	2	6	3	3/11/99	PCT	A61K	31/44		
WO	9	9	2	1	5	6	2	5/6/99	PCT	A61K	31/557		
WO	9	9	2	4	4	3	3	5/20/99	PCT	C07D	487/04		
WO	9	9	5	4	3	3	3	10/28/99	PCT	C07D	487/04		
WO	0	0	1	2	0	7	5	3/9/00	PCT	A61K	31/13		
WO	0	0	2	3	0	9	1	4/27/00	PCT	A61K	38/00		

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>							ATTY. DOCKET NO. PC25489A			SERIAL NO. 10/799,191					
							APPLICANT Gillian Munro Burgess, et al.			FILING DATE March 12, 2004			GROUP To Be Assigned		
							WO	0	0	2	4	7	4	5	5/4/00
WO	0	0	2	7	8	4	8	5/18/00	PCT	C07D	487/04				
WO	0	0	5	9	5	1	0	10/12/00	PCT	A61K	31/505				
WO	0	1	2	7	1	1	2	4/19/01	PCT	C07D	487/04				
WO	0	1	2	7	1	1	3	4/19/01	PCT	C07D	487/04				
WO	0	1	4	7	4	9	5	7/5/01	PCT	A61K	9/14				
WO	0	2	7	2	5	8	6	9/19/02	PCT	C07D	487/04				
WO	0	2	7	4	3	1	2	9/26/02	PCT	A61K	31/505				
WO	0	2	7	4	7	7	4	9/26/02	PCT	C07D	487/04				
WO	0	2	7	9	2	0	3	10/10/02	PCT	C07D	487/04				
WO	0	2	1	3	7	9	8	2/21/02	PCT	A61K	31/00				
WO	0	2	2	2	5	5	8	3/21/02	PCT	C07C	251/00				
WO	0	2	2	2	5	5	9	3/21/02	PCT	C07C	251/00				
WO	0	2	2	2	5	6	1	3/21/02	PCT	C07C	257/14				
WO	0	2	2	2	5	6	2	3/21/02	PCT	C07C	257/14				
EP	0	4	6	3	7	5	6	1/2/92	EP	C07D	487/04				
EP	0	5	2	6	0	0	4	10/8/97	EP	C07D	487/04				
EP	0	9	9	5	7	5	0	4/26/00	EP	C07D	487/04				
EP	0	9	9	5	7	5	1	4/26/00	EP	C07D	487/04				
EP	1	0	9	2	7	1	8	4/18/01	EP	C07D	473/30				
EP	1	0	9	2	7	1	9	5/28/03	EP	C07D	487/04				
EP	1	0	9	7	7	1	9	5/9/01	EP	A61K	38/55				
EP	1	2	4	1	1	7	0	9/18/02	EP	C07D	487/14				
JP	8-	2	0	8	4	7	5	8/13/96	JP	A61K	31/445	X			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
			Ballard, et al. "Effects of Sildenafil on the Relaxation of Human Corpus Cavernosum Tissue in Vitro and on the Activities of Cyclic Nucleotide Phosphodiesterase Isozymes", <u>The Journal of Urology</u> 159(6), pp. 2164-2171 (1998)												
			Thompson, et al., "Purification and Characterization of High-Affinity Cyclic Adenosine Monophosphate Phosphodiesterase from Dog Kidney", <u>Biochemistry</u> , pp. 5228-5237 (1979)												
			Rotella, et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of												

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25489A	SERIAL NO. 10/799,191
		APPLICANT Gillian Munro Burgess, et al.	
		FILING DATE March 12, 2004	GROUP To Be Assigned
Erectile Dysfunction", <u>J. Med. Chem.</u> 43 , pp. 1257-1263 (2000)			
Thompson, et al., "New Prospects for Lipid-Lowering Drugs", <u>Exp. Op. on Invest. Drugs</u> 7 (5), pp. 715-727 (1998)			
Ari, et al., "Nitric Oxide and Penile Erection in Streptozotocin-Diabetic Rats", <u>Clinical Science</u> 96 , pp. 365-371 (1999)			
Finnin, et al., "Transdermal Penetration Enhancers: Applications, Limitations, and Potential", <u>J. Pharm. Sci.</u> 88 (10), pp. 955-958 (1999)			
Halebian, "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications", <u>J. Pharm. Sci.</u> 64 (8), pp. 1269-1288 (1975)			
Liang, et al., "Fast-dissolving Intraoral Drugs Delivery Systems", <u>Expert Opin. Ther. Patents</u> 11 (6), pp. 981-986 (2001)			
Ballard, et al., "Sildenafil, a Potent Selective Inhibitor of Type 5 Phosphodiesterase, Enhances Nitric Oxide-Dependent Relaxation of Rabbit Corpus Cavernosum", <u>Brit. J. Pharmacol.</u> 118 (suppl.), abstract 153P (1996)			
"Hypolipidemic HMG-CoA Reductase Inhibitor", <u>Drugs of the Future</u> 19 (6), pp. 537-541 (1994)			
<u>Drugs of the Future</u> 20 (6), p. 611 (1995)			
<u>Drugs of the Future</u> 21 (6), p. 642 (1996)			
"HMG-COA-Reduktase Hemmer – Im Ueberblick", <u>Pharmazie in unserer Zeit</u> 28 (3), pp. 147-152 (1999)			
Verma, et al., "Current Status of Drug Delivery Technologies and Future Directions", <u>Pharmaceutical Technology On-line</u> 25 (2), pp. 1-14 (2001)			
http://www.genetichealth.com/DBTS What Is Type 1 Diabetes.shtml			
http://www.merck.com/mrkshared/mmanual/section2/chapter13/13a.htm			
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			